Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Protagonist Therapeutics to similar companies based on the strength of its risk, valuation, earnings, profitability, dividends, institutional ownership and analyst recommendations.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Protagonist Therapeutics and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Protagonist Therapeutics | 0 | 0 | 16 | 1 | 3.06 |
| Protagonist Therapeutics Competitors | 9903 | 15310 | 45655 | 1602 | 2.54 |
Protagonist Therapeutics currently has a consensus price target of $166.67, indicating a potential upside of 27.28%. As a group, “Biotechnology” companies have a potential upside of 127.13%. Given Protagonist Therapeutics’ rivals higher probable upside, analysts clearly believe Protagonist Therapeutics has less favorable growth aspects than its rivals.
Insider & Institutional Ownership
98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Protagonist Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Protagonist Therapeutics | 62.04% | 42.83% | 40.29% |
| Protagonist Therapeutics Competitors | -12,319.70% | -407.93% | -30.95% |
Earnings & Valuation
This table compares Protagonist Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Protagonist Therapeutics | $46.02 million | -$130.15 million | 27.74 |
| Protagonist Therapeutics Competitors | $713.66 million | $10.27 million | -18.80 |
Protagonist Therapeutics’ rivals have higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Protagonist Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics’ rivals have a beta of -1.90, suggesting that their average share price is 290% less volatile than the S&P 500.
Summary
Protagonist Therapeutics beats its rivals on 9 of the 13 factors compared.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
